Trials / No Longer Available

No Longer AvailableNCT05014724

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Status: No Longer Available
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: UCB Biopharma SRL · Industry
Sex: All
Age: 18 Years
Healthy volunteers: —

Summary

This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventions

Type	Name	Description
DRUG	Rozanolixizumab	Rozanolixizumab is dosed weekly. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.

Timeline

First posted: 2021-08-20
Last updated: 2024-01-25

Source: ClinicalTrials.gov record NCT05014724. Inclusion in this directory is not an endorsement.